Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant

Rahul Thakur, Toulon O'Connor, Cynthia DeWitt, Frank Kuhr, James Driscoll, Ehsan Malek

Blood (2025) 146 (Supplement 1): 4075.

https://doi.org/10.1182/blood-2025-4075

Published: 2025

Journal Articles

Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma

Rahul Thakur, James Driscoll, Jennifer Ahlstrom, Jay Hydren, Mason Barnes, Juan Pablo Capdevila, Brian Betts, Marco Davila, Shernan Holtan, Jorge Arturo Hurtado Martinez, Ehsan Malek

Blood (2025) 146 (Supplement 1): 2810.

https://doi.org/10.1182/blood-2025-2810

Published: 2025

Journal Articles

Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States

Ehsan Malek, Juan Pablo Capdevila, Rahul Thakur, Mason Barnes, Jay Hydren, Jennifer Ahlstrom, James Driscoll, Marco Davila, Shernan Holtan, Brian Betts, Karla Mariana Castro Bórquez, Jorge Arturo Hurtado Martinez

Blood (2025) 146 (Supplement 1): 2809.

https://doi.org/10.1182/blood-2025-2809

Published: 2025

Journal Articles

Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma

James Driscoll, James Ignatz-Hoover, Ehsan Malek, John D'Cruz, Wei Huang, Derek Taylor

Blood (2025) 146 (Supplement 1): 2176.

https://doi.org/10.1182/blood-2025-2176

Published: 2025

Journal Articles

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling

Ehsan Malek, Megan Herr, James Driscoll, Paul Wallace, Marco Davila, Brian Betts, Shernan Holtan, Hamza Hassan, Theresa Hahn, Han Yu

Blood (2025) 146 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2025-3935

Published: 2025

Journal Articles

Comorbidities and outcomes in patients with Acute Myeloid Leukemia with and without type II diabetes mellitus admitted for chemotherapy: A national inpatient sample analysis

Harshank Patel, Rahul Mishra, Fehmida Laxmidhar, Ayema Haque, Vanita Motiani, Krishna Doshi, Chalothorn Wannaphut, Madison Laird, Megan Moore, Hannah Wheeler, Kirsten Hickok, Ehsan Malek, Akshay Amaraneni, Hemasri Tokala, Philip Kroth

Blood (2025) 146 (Supplement 1): 4632.

https://doi.org/10.1182/blood-2025-4632

Published: 2025

Journal Articles

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

James J Ignatz-Hoover, Pryianka Rana, John D'Cruz, E Ricky Chan, Ehsan Malek, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2024-211260

Published: 2024

Journal Articles

Speeding up Myeloma Care: Robust Machine Learning Predictions of M-Spike Levels

Ehsan Malek, Juan Pablo Capdevila, Jennifer M. Ahlstrom, Jorge Arturo Hurtado Martinez, Gi-Ming Wang, Jay R. Hydren, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7604.

https://doi.org/10.1182/blood-2024-200888

Published: 2024

Journal Articles

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Blood (2024) 144 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2024-211352

Published: 2024

Journal Articles

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

Ehsan Malek, James J Ignatz-Hoover, Priyanka S. Rana, James J. Driscoll, II

Blood (2024) 144 (Supplement 1): 7042.

https://doi.org/10.1182/blood-2024-211233

Published: 2024

Journal Articles

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Blood (2024) 144 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2024-207459

Published: 2024

Journal Articles

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

Ehsan Malek, Marco Davila, Hector Tirado, Shernan G. Holtan, Brian Betts, Han Yu

Blood (2024) 144 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2024-200893

Published: 2024

Journal Articles

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

James J. Driscoll, II, Ehsan Malek, Priyanka S. Rana, James J Ignatz-Hoover

Blood (2024) 144 (Supplement 1): 6832.

https://doi.org/10.1182/blood-2024-211485

Published: 2024

Journal Articles

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Ehsan Malek, Kimberly Crasti, Grant Schofield, Shernan G. Holtan, Megan M Herr, Marco Davila, You-Wen Qian, Brian Betts, Mackenzie Lieberman, Jason Tong, Colin Chavel, Kelvin P. Lee, Scott Olejniczak

Blood (2024) 144 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2024-198255

Published: 2024

Journal Articles

Machine Learning in Myeloma: Do Racial Differences Influences Systemic Impact of Multiple Myeloma?

Hector Tirado, Jorge Arturo Hurtado Martinez, Jennifer M. Ahlstrom, Jay R. Hydren, Juan Pablo Capdevila, James J. Driscoll, II, Gi-Ming Wang, Ehsan Malek

Blood (2024) 144 (Supplement 1): 7840.

https://doi.org/10.1182/blood-2024-208026

Published: 2024

Journal Articles

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

Jeries Kort, Sathya Sri Areti, Nikolas Naleid, Brenda W Cooper, Ehsan Malek

Blood (2023) 142 (Supplement 1): 6706.

https://doi.org/10.1182/blood-2023-190931

Published: 2023

Journal Articles

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

Priyanka S. Rana, James J. Ignatz-Hoover, Ehsan Malek, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2023-189262

Published: 2023

Journal Articles

Assessing a New Paradigm in Defining High Risk Precursor Disease State for Patients with Plasma Cell Dyscrasia: Fluctuating Monoclonal Protein

Rishi Chopra, Pingfu Fu, Jeries Kort, Ravikumar Kyasaram, Ehsan Malek

Blood (2023) 142 (Supplement 1): 6774.

https://doi.org/10.1182/blood-2023-172709

Published: 2023

Journal Articles

Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma

Ehsan Malek, Gi-Ming Wang, Jennifer Cullen, Curtis Tatsuoka, Anant Madabhushi, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 7343.

https://doi.org/10.1182/blood-2023-172742

Published: 2023

Journal Articles

Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma

Ehsan Malek, Rishi Chopra, James J. Driscoll, II, Pingfu Fu

Blood (2023) 142 (Supplement 1): 7409.

https://doi.org/10.1182/blood-2023-172712

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant

Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma

Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States

Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling

Comorbidities and outcomes in patients with Acute Myeloid Leukemia with and without type II diabetes mellitus admitted for chemotherapy: A national inpatient sample analysis

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

Speeding up Myeloma Care: Robust Machine Learning Predictions of M-Spike Levels

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

The TGFβ Type I Receptor Kinase Inhibitor Vactosertib Improves T-Cell Fitness in Relapsed/Refractory Multiple Myeloma: A Phase 1b Trial

A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

A Novel Immunoproteasome Activator That Expands and Amplifies the Multiple Myeloma Immunopeptidome and Promotes Cytotoxic T-Cell Activity

Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Machine Learning in Myeloma: Do Racial Differences Influences Systemic Impact of Multiple Myeloma?

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

HDAC6 Inhibition Activates Proteasomes to Modulate the MHC Class I Immunopeptidome and Promote Antimyeloma Immunity

Assessing a New Paradigm in Defining High Risk Precursor Disease State for Patients with Plasma Cell Dyscrasia: Fluctuating Monoclonal Protein

Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma

Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only